OPPI appeals for price control exemption on patented and orphan drugs

The Organization of Pharmaceutical Producers of India (OPPI) has urged the government to exempt patented and orphan drugs from price control.

During a recent meeting with the Department of Pharmaceuticals (DoP), the OPPI argued that current price control regulations tend to impede innovation and economic incentives for inventors.

The OPPI pointed out that the provision in Paragraph 32 of the Drug Price Control Order (DPCO) allows the National Pharmaceutical Pricing Authority (NPPA) to exempt certain drugs from price control for five years if they are developed through unique and indigenous processes and are patented under the Indian Patents Act.